Claversal
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Aim : To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release…
Rectally administered mesalazine (5‐aminosalicylic acid) is a recognized therapy for distal ulcerative colitis. It is frequently…
When Asacol commands 65% of the UK market, can so many British gastroenterologists be wrong? Possibly. The market leader in…
In a double-blind, single-center, 1-year prospective trial, we compared a pH-dependent Eudragit L-coated formulation of oral 5…
Investigators: This multicentre study was conducted by 29 principal investigators in 11 countries.
Intramucosal 5-aminosalicylic acid (5-ASA) and acetylated 5-ASA (Ac-5-ASA) concentrations were determined in ileocolonic biopsy…
The bioavailability of three pure 5‐aminosalicylic (5‐ASA) preparations (Asacol, Claversal, and Pentasa) was studied in 8…
A randomized, double‐blind, placebo‐controlled multicentre study was undertaken to evaluate the safety and efficacy of coated…
Gastrointestinal transit and release of a delayed-release, enteric-coated tablet of mesalazine (Claversal) were studied in 13…
The safety and efficacy of Claversal (coated, oral 5‐aminosalicylic acid (5‐ASA) 0.75 g/day) and sulphasalazine 1.5–2.0 g/day…